About Evelo Biosciences
Evelo Biosciences is a company based in Cambridge (United States) founded in 2015. Evelo Biosciences has raised $166.5 million across 4 funding rounds from investors including Flagship Pioneering, Celgene and Google Ventures. Evelo Biosciences has completed 1 acquisition, including Epiva Therapeutics. Evelo Biosciences operates in a competitive market with competitors including Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evelo Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$114.53 M (USD)6.26as on Dec 31, 2022
-
EBITDA
-$103.51 M (USD)7.03as on Dec 31, 2022
-
Total Equity Funding
$166.5 M (USD)
in 4 rounds
-
Latest Funding Round
$25.5 M (USD), Post-IPO
Jul 10, 2023
-
Investors
Flagship Pioneering
& 4 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Evelo Biosciences
Evelo Biosciences is a publicly listed company on the OTC with ticker symbol EVLO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Evelo Biosciences
Unlock access to complete
Funding Insights of Evelo Biosciences
Evelo Biosciences has successfully raised a total of $166.5M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.5 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evelo Biosciences
Evelo Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Flagship Pioneering, Celgene and Google Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Early stage investments focused VC firm
|
Locked | Locked | Locked |
Investor details for Evelo Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evelo Biosciences
Evelo Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Epiva Therapeutics.
Investment portfolio details for Evelo Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Microbiome-based therapeutics are developed for autoimmune diseases.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Evelo Biosciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Evelo Biosciences
Detailed financials for Evelo Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evelo Biosciences Comparisons
Peer comparison for Evelo Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evelo Biosciences
Evelo Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
Detailed competitors of Evelo Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evelo Biosciences
Complete news archive for Evelo Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evelo Biosciences
Evelo Biosciences was founded in 2015.
Evelo Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Simba Gill is the current CEO of Evelo Biosciences.
Evelo Biosciences is a funded company, having raised a total of $166.5M across 4 funding rounds to date.
Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.
Evelo Biosciences's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Yes, Evelo Biosciences is publicly traded on OTC under the ticker symbol EVLO.
Evelo Biosciences has made 1 acquisition, including Epiva Therapeutics.
Evelo Biosciences has 5 investors. Key investors include Flagship Pioneering, Celgene, Google Ventures, Acks, and Mayo Clinic Ventures.
The ticker symbol of Evelo Biosciences is EVLO on OTC.